In January 2019, the U.S. Food and Drug Administration (FDA) updated a 2015 draft guidance on rare diseases. Although essentially agreeing with the changes, several organizations, both patient advocacy and industry groups, have called on the FDA to make additional changes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,